291 related articles for article (PubMed ID: 30753828)
21. Epigenetic alterations in colorectal cancer: the CpG island methylator phenotype.
Bae JM; Kim JH; Kang GH
Histol Histopathol; 2013 May; 28(5):585-95. PubMed ID: 23341177
[TBL] [Abstract][Full Text] [Related]
22. Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer.
Slattery ML; Curtin K; Sweeney C; Levin TR; Potter J; Wolff RK; Albertsen H; Samowitz WS
Int J Cancer; 2007 Feb; 120(3):656-63. PubMed ID: 17096326
[TBL] [Abstract][Full Text] [Related]
23. A hypermorphic epithelial β-catenin mutation facilitates intestinal tumorigenesis in mice in response to compounding WNT-pathway mutations.
Buchert M; Rohde F; Eissmann M; Tebbutt N; Williams B; Tan CW; Owen A; Hirokawa Y; Gnann A; Orend G; Orner G; Dashwood RH; Heath JK; Ernst M; Janssen KP
Dis Model Mech; 2015 Nov; 8(11):1361-73. PubMed ID: 26398937
[TBL] [Abstract][Full Text] [Related]
24. Oncosuppressor methylation: a possible key role in colon metastatic progression.
Tommasi S; Pinto R; Petriella D; Pilato B; Lacalamita R; Santini D; Zito F; Colucci G; Paradiso A; Silvestris N
J Cell Physiol; 2011 Jul; 226(7):1934-9. PubMed ID: 21506124
[TBL] [Abstract][Full Text] [Related]
25. Genetic editing of colonic organoids provides a molecularly distinct and orthotopic preclinical model of serrated carcinogenesis.
Lannagan TRM; Lee YK; Wang T; Roper J; Bettington ML; Fennell L; Vrbanac L; Jonavicius L; Somashekar R; Gieniec K; Yang M; Ng JQ; Suzuki N; Ichinose M; Wright JA; Kobayashi H; Putoczki TL; Hayakawa Y; Leedham SJ; Abud HE; Yilmaz ÖH; Marker J; Klebe S; Wirapati P; Mukherjee S; Tejpar S; Leggett BA; Whitehall VLJ; Worthley DL; Woods SL
Gut; 2019 Apr; 68(4):684-692. PubMed ID: 29666172
[TBL] [Abstract][Full Text] [Related]
26. Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer.
Nagasaka T; Koi M; Kloor M; Gebert J; Vilkin A; Nishida N; Shin SK; Sasamoto H; Tanaka N; Matsubara N; Boland CR; Goel A
Gastroenterology; 2008 Jun; 134(7):1950-60, 1960.e1. PubMed ID: 18435933
[TBL] [Abstract][Full Text] [Related]
27. Human skin neural crest progenitor cells are susceptible to BRAF(V600E)-induced transformation.
Kumar SM; Dai J; Li S; Yang R; Yu H; Nathanson KL; Liu S; Zhou H; Guo J; Xu X
Oncogene; 2014 Feb; 33(7):832-41. PubMed ID: 23334329
[TBL] [Abstract][Full Text] [Related]
28. Targeting of super-enhancers and mutant BRAF can suppress growth of BRAF-mutant colon cancer cells via repression of MAPK signaling pathway.
Nakamura Y; Hattori N; Iida N; Yamashita S; Mori A; Kimura K; Yoshino T; Ushijima T
Cancer Lett; 2017 Aug; 402():100-109. PubMed ID: 28576751
[TBL] [Abstract][Full Text] [Related]
29. The MLH1 -93 G>A promoter polymorphism and genetic and epigenetic alterations in colon cancer.
Samowitz WS; Curtin K; Wolff RK; Albertsen H; Sweeney C; Caan BJ; Ulrich CM; Potter JD; Slattery ML
Genes Chromosomes Cancer; 2008 Oct; 47(10):835-44. PubMed ID: 18615680
[TBL] [Abstract][Full Text] [Related]
30. Pan-cancer methylation and expression profiling of adenocarcinomas revealed epigenetic silencing in the WNT signaling pathway.
Li J; Huang KL; Zhang T; Li H; Zhao J; Wang H
Neoplasma; 2016; 63(2):208-14. PubMed ID: 26774141
[TBL] [Abstract][Full Text] [Related]
31. Transgenic expression of oncogenic BRAF induces loss of stem cells in the mouse intestine, which is antagonized by β-catenin activity.
Riemer P; Sreekumar A; Reinke S; Rad R; Schäfer R; Sers C; Bläker H; Herrmann BG; Morkel M
Oncogene; 2015 Jun; 34(24):3164-75. PubMed ID: 25109331
[TBL] [Abstract][Full Text] [Related]
32. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.
Ogino S; Nosho K; Kirkner GJ; Kawasaki T; Meyerhardt JA; Loda M; Giovannucci EL; Fuchs CS
Gut; 2009 Jan; 58(1):90-6. PubMed ID: 18832519
[TBL] [Abstract][Full Text] [Related]
33. High frequency of genes' promoter methylation, but lack of BRAF V600E mutation among Iranian colorectal cancer patients.
Naghibalhossaini F; Hosseini HM; Mokarram P; Zamani M
Pathol Oncol Res; 2011 Dec; 17(4):819-25. PubMed ID: 21455633
[TBL] [Abstract][Full Text] [Related]
34. DNA methylation subgroups and the CpG island methylator phenotype in gastric cancer: a comprehensive profiling approach.
Loh M; Liem N; Vaithilingam A; Lim PL; Sapari NS; Elahi E; Mok ZY; Cheng CL; Yan B; Pang B; Salto-Tellez M; Yong WP; Iacopetta B; Soong R
BMC Gastroenterol; 2014 Mar; 14():55. PubMed ID: 24674026
[TBL] [Abstract][Full Text] [Related]
35. CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels.
Lee S; Cho NY; Yoo EJ; Kim JH; Kang GH
Arch Pathol Lab Med; 2008 Oct; 132(10):1657-65. PubMed ID: 18834226
[TBL] [Abstract][Full Text] [Related]
36. Frequent silencing of RASSF1A via promoter methylation in follicular thyroid hyperplasia: a potential early epigenetic susceptibility event in thyroid carcinogenesis.
Brown TC; Juhlin CC; Healy JM; Prasad ML; Korah R; Carling T
JAMA Surg; 2014 Nov; 149(11):1146-52. PubMed ID: 25229773
[TBL] [Abstract][Full Text] [Related]
37. Molecular dissection of premalignant colorectal lesions reveals early onset of the CpG island methylator phenotype.
Yamamoto E; Suzuki H; Yamano HO; Maruyama R; Nojima M; Kamimae S; Sawada T; Ashida M; Yoshikawa K; Kimura T; Takagi R; Harada T; Suzuki R; Sato A; Kai M; Sasaki Y; Tokino T; Sugai T; Imai K; Shinomura Y; Toyota M
Am J Pathol; 2012 Nov; 181(5):1847-61. PubMed ID: 22995252
[TBL] [Abstract][Full Text] [Related]
38. B vitamins, methionine and alcohol intake and risk of colon cancer in relation to BRAF mutation and CpG island methylator phenotype (CIMP).
Schernhammer ES; Giovannucci E; Baba Y; Fuchs CS; Ogino S
PLoS One; 2011; 6(6):e21102. PubMed ID: 21738611
[TBL] [Abstract][Full Text] [Related]
39. Aberrant TET1 Methylation Closely Associated with CpG Island Methylator Phenotype in Colorectal Cancer.
Ichimura N; Shinjo K; An B; Shimizu Y; Yamao K; Ohka F; Katsushima K; Hatanaka A; Tojo M; Yamamoto E; Suzuki H; Ueda M; Kondo Y
Cancer Prev Res (Phila); 2015 Aug; 8(8):702-11. PubMed ID: 26063725
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic silencing of TSHR gene in thyroid cancer patients in relation to their BRAF V600E mutation status.
Khan MS; Pandith AA; Masoodi SR; Wani KA; Ul Hussain M; Mudassar S
Endocrine; 2014 Nov; 47(2):449-55. PubMed ID: 24927793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
